drugset
drugset / Trial / NCT05083208

PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

NCT05083208 ↗

Phase 1 Terminated 12 enrolled Henan Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective single-arm, multicenter, phase Ib clinical trial of PI3Kδ inhibitor Parsaclisib combined with chidamide for the treatment of relapsed/refractory peripheral T-cell lymphoma.

Timeline

Start
2022-02-20
Primary completion
2024-06-30
Completion
2025-08-01

Outcome

Outcome not reported

Stopped: “The clinical development of parsaclisib was stopped by it's manufacturer.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Parsaclisib Unknown 2.5 mg Oral
Subject Parsaclisib Unknown 10 mg Oral
Subject Parsaclisib Unknown 15 mg Oral
Subject Parsaclisib Unknown 20 mg Oral
Subject Tucidinostat Small molecule 20 mg Oral

Indications

peripheral T-cell lymphoma, not otherwise specified